Uveitis Pipeline Drugs & Key Companies Insight Report 2023 | Companies: Santen, EyeGate Pharmaceuticals, Sanofi Aventis, Oculis Pharma,Clearside Biomedical

Uveitis Pipeline Insights 2023

DelveInsight’s “Uveitis Pipeline Insight 2023” report provides comprehensive insights about key companies and pipeline drugs in the Uveitis pipeline landscapes. 

The report comprises Uveitis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Uveitis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Uveitis pipeline products.     

Uveitis Overview

Uveitis is a term for inflammation of the eye. It is an inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. It is caused by inflammatory responses inside the eye that can be caused due to tissue damage, germs, or toxins which lead swelling, redness, heat, and destroys tissues as certain white blood cells rush to the affected part.

Uveitis is classified anatomically as anterior, intermediate, posterior, or diffuse. Anterior uveitis typically refers to inflammation of the iris and anterior chamber; intermediate uveitis refers to inflammation of the ciliary body and vitreous humor (the jellylike filling in the anterior portion of the eye); and posterior uveitis refers to inflammation of the retina, choroid, or the optic disk (where the optic nerve enters the retina). Diffuse uveitis (Panuveitis) implies inflammation of the entire uveals tract.

Some of the key takeaways from the Uveitis Pipeline Report:

• Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Santen, EyeGate Pharmaceuticals, Sanofi Aventis, Oculis Pharma,Clearside Biomedical,   etc., are developing therapies for the treatment of Uveitis.
• Emerging therapies such as Sirolimus, EGP-437, Sarilumab, LME636 (OCS-02), XIPERE formerly known as Suprachoroidal CLS-TA, are expected to have a significant impact on the  Uveitis market in the coming years.

Get an overview of pipeline landscape @ Uveitis Clinical Trials Analysis 

Uveitis Pipeline Therapies along with Key Players:

• Sirolimus: Santen
• EGP-437: EyeGate Pharmaceuticals
• Sarilumab: Sanofi Aventis
• LME636 (OCS-02): Oculis Pharma
• XIPERE formerly known as Suprachoroidal CLS-TA: Clearside Biomedical

Scope of Uveitis Pipeline Drug Insight    

• Coverage: Global 
• Major Players: Santen, EyeGate Pharmaceuticals, Sanofi Aventis, Oculis Pharma,Clearside Biomedical, and others.
• Pipeline Therapies: Sirolimus, EGP-437, Sarilumab, LME636 (OCS-02), XIPERE formerly known as Suprachoroidal CLS-TA, and others.

Table of Contents

To know more about Uveitis therapeutic assessment, click here.

Related Reports:

Uveitis Market

DelveInsight’s ‘Uveitis-Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), 

Uveitis Epidemiology

DelveInsight’s ‘Uveitis Epidemiology Forecast to 2032′ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/